Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LELAND N ALLEN

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1245258573
CMS profile
55913
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$344.62

27 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $344.62 27

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LELAND N ALLEN

NPI 1245258573 · CMS profile ID 55913

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245258573?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245258573?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245258573?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
LELAND N ALLEN, NPI 1245258573, CMS profile ID 55913, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–27 of 27 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1245258573?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

27 matching records · $344.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 27 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–27 of 27.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $19.3412/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741196497 CMS
Allergan, Inc. $6.7112/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205295 CMS
Allergan, Inc. $4.4512/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205297 CMS
Allergan, Inc. $7.0912/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205293 CMS
Amgen Inc. $13.7011/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741196495 CMS
Amarin Pharma Inc. $12.0311/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739945179 CMS
Gilead Sciences, Inc. $12.1710/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747950629 CMS
Allergan, Inc. $13.2410/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205291 CMS
Allergan, Inc. $12.1510/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205289 CMS
Novo Nordisk Inc $12.5209/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744927189 CMS
Amgen Inc. $13.5609/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741196493 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.6509/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720803201 CMS
Allergan, Inc. $11.2909/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205287 CMS
Astellas Pharma US Inc $13.6708/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718293663 CMS
Lilly USA, LLC $19.8107/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728538783 CMS
Allergan, Inc. $13.7507/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205285 CMS
Allergan, Inc. $10.7906/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205283 CMS
Allergan, Inc. $10.5806/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205281 CMS
Allergan, Inc. $11.9405/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205279 CMS
Allergan, Inc. $6.7104/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205277 CMS
Novo Nordisk Inc $12.5802/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744731265 CMS
Allergan, Inc. $7.0902/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205275 CMS
Allergan, Inc. $18.7302/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205273 CMS
Merck Sharp & Dohme Corporation $19.6501/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747747733 CMS
Melinta Therapeutics, LLC $23.3601/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752665049 CMS
Gilead Sciences, Inc. $13.4001/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747950627 CMS
Allergan, Inc. $8.6601/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723205271 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,146.19 68
PY2020 $344.62 27
PY2021 $468.66 29
PY2022 $127.11 7
PY2023 $45.03 3
PY2024 $368.99 13
PY2025 $356.74 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $394,977.43 20
PY2023 Principal investigator $532,033.34 44
PY2022 Principal investigator $2,884,761.18 187
PY2021 Principal investigator $4,662,082.09 207

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $34,000.00 12/27/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045869471
Principal investigator 1 PFIZER INC. $5,274.36 12/21/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045990543
Principal investigator 1 PFIZER INC. $2,176.20 08/22/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046220471
Principal investigator 1 PFIZER INC. $6,073.86 07/06/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045890207
Principal investigator 1 PFIZER INC. $869.40 06/29/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046328487
Principal investigator 1 PFIZER INC. $11,401.56 06/27/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045890240
Principal investigator 1 PFIZER INC. $347.76 06/22/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046332385
Principal investigator 1 PFIZER INC. $5,633.74 06/16/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046330031
Principal investigator 1 PFIZER INC. $2,260.44 06/14/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046312833
Principal investigator 1 PFIZER INC. $16,097.20 06/08/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045890221
Principal investigator 1 PFIZER INC. $23,352.99 06/03/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046062263
Principal investigator 1 PFIZER INC. $24,144.48 05/26/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045887365
Principal investigator 1 PFIZER INC. $6,244.72 05/25/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046357229
Principal investigator 1 PFIZER INC. $1,043.28 05/16/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046149777
Principal investigator 1 PFIZER INC. $17,575.68 05/09/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045887379
Principal investigator 1 ModernaTX, Inc. $150.00 05/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141575
Principal investigator 1 PFIZER INC. $50,033.09 03/09/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045947137
Principal investigator 1 PFIZER INC. $9,785.58 03/07/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046184579
Principal investigator 1 PFIZER INC. $6,259.68 02/28/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046149389
Principal investigator 1 ModernaTX, Inc. $195.00 02/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141545
Principal investigator 1 ModernaTX, Inc. $13,587.44 02/17/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142715
Principal investigator 1 PFIZER INC. $811.88 02/17/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046298541
Principal investigator 1 ModernaTX, Inc. $18,276.30 02/15/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142701
Principal investigator 1 PFIZER INC. $6,433.56 02/08/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045887393
Principal investigator 1 ModernaTX, Inc. $345.00 02/03/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141529
Principal investigator 1 ModernaTX, Inc. $15,481.81 02/03/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142673
Principal investigator 1 ModernaTX, Inc. $2,270.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141371
Principal investigator 1 ModernaTX, Inc. $200.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141385
Principal investigator 1 ModernaTX, Inc. $495.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141417
Principal investigator 1 ModernaTX, Inc. $450.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141431
Principal investigator 1 ModernaTX, Inc. $49,790.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141459
Principal investigator 1 ModernaTX, Inc. $1,500.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141473
Principal investigator 1 ModernaTX, Inc. $700.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141501
Principal investigator 1 ModernaTX, Inc. $425.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141515
Principal investigator 1 ModernaTX, Inc. $60,231.61 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142507
Principal investigator 1 ModernaTX, Inc. $3,847.50 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142523
Principal investigator 1 ModernaTX, Inc. $46,704.66 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142567
Principal investigator 1 ModernaTX, Inc. $256.50 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142581
Principal investigator 1 ModernaTX, Inc. $8,505.00 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142595
Principal investigator 1 ModernaTX, Inc. $71,366.54 02/01/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041142631
Principal investigator 1 ModernaTX, Inc. $2,000.70 01/20/2023 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1041141343
Principal investigator 1 PFIZER INC. $4,392.54 01/18/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045885811
Principal investigator 1 PFIZER INC. $173.88 01/12/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046160203
Principal investigator 1 PFIZER INC. $869.40 01/11/2023 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046352645